Haystack MRD

Haystack MRD's mission is to deliver confidence in cancer management through its high-precision, tumor-informed MRD liquid biopsy test. The company has successfully commercialized its proprietary, dual-strand sequencing technology, achieving a market-leading analytical sensitivity with a limit of detection of 0.0006%. Its core strategy leverages the vast clinical laboratory infrastructure, regulatory expertise, and commercial scale of its parent company, Quest Diagnostics, to rapidly penetrate the growing MRD market and establish a new standard of care in oncology.

A tumor-informed, next-generation sequencing (NGS) liquid biopsy platform utilizing a proprietary dual-strand error-correction method to detect circulating tumor DNA (ctDNA) with an ultra-low limit of detection of 0.0006%.

Haystack MRD competes in the high-sensitivity tumor-informed MRD segment against leader Natera (Signatera) and others like Guardant Health. Its primary competitive advantages are its ultra-sensitive dual-strand technology and the vast commercial infrastructure of its parent company, Quest Diagnostics.